plasmid
dna
mrna
vaccin
gener
signific
interest
effort
potenti
platform
technolog
could
use
varieti
applic
rang
prophylaxi
therapi
person
medicin
global
health
solut
quickli
made
fairli
gener
manufactur
process
construct
directli
genet
sequenc
desir
protein
whether
origin
protein
human
pathogen
vaccin
make
gene
construct
code
antigen
instead
inactiv
attenu
pathogen
instead
make
recombin
protein
vastli
easier
rapid
avoid
potenti
risk
work
live
pathogen
likewis
vaccin
construct
encod
key
antigen
without
includ
protein
may
either
deleteri
toxin
may
irrelev
protect
yet
immunodomin
eas
speed
make
construct
also
mean
consid
potenti
gamechang
target
epidem
emerg
diseas
rapidli
design
construct
manufactur
vaccin
crucial
cancer
rather
reli
tumorassoci
antigen
common
mani
tumor
would
requir
littl
effort
make
vaccin
specif
individu
exact
tumor
antigen
refer
person
vaccin
concept
demonstr
preclin
dna
vaccin
target
lymphoma
idiotyp
tumor
could
rapidli
sequenc
dna
vaccin
made
much
quickli
recombin
protein
version
altern
test
mrna
librari
genebas
construct
encod
variou
antigen
could
made
base
patient
individu
tumor
antigen
combin
construct
could
easili
combin
premad
librari
time
mani
scientist
turn
plasmid
dna
explor
mrna
technolog
remain
uncertain
whether
dna
vaccin
licens
human
diseas
use
compar
two
technolog
analyz
theoret
issu
experiment
data
progress
felgner
colleagu
publish
scienc
demonstr
socal
nake
dna
plasmid
dna
formul
transfect
agent
could
directli
inject
muscl
result
express
encod
protein
myocyt
observ
import
signific
effort
devot
formul
deliv
dna
vivo
mani
compound
use
vitro
transfect
surpris
simplic
approach
gener
signific
interest
soon
shown
plasmid
dna
code
conserv
intern
influenza
protein
could
gener
protect
preclin
mous
model
influenza
challeng
differ
influenza
strain
strain
protein
antigen
sequenc
mani
group
began
develop
plasmid
dna
vaccin
cancer
immunotherapi
immun
intervent
autoimmun
allerg
diseas
public
also
demonstr
nake
rna
could
similarli
result
vivo
express
encod
protein
howev
attent
focus
util
plasmid
dna
rather
mrna
like
concern
instabl
mrna
bloom
colleagu
demonstr
efficaci
mrna
express
protein
vivo
show
mrna
encod
hormon
could
correct
diseas
follow
direct
inject
rat
brain
year
first
demonstr
abil
dna
plasmid
protect
mice
heterosubtyp
challeng
influenza
publish
liposomeformul
mrna
also
shown
gener
influenzaspecif
cytolyt
cell
mice
although
protect
infecti
challeng
shown
plasmid
dna
test
perhap
explain
part
differ
excit
technolog
nevertheless
entiti
key
issu
optim
deliv
dna
plasmid
mrna
desir
cell
either
optim
express
desir
therapeut
protein
drug
gene
therapi
suppli
miss
defect
protein
gener
desir
immun
respons
protein
antigen
gene
therapi
encod
protein
need
stimul
immun
respons
vaccin
cell
produc
protein
encod
mrna
plasmid
dna
key
issu
although
antibodi
protein
would
like
need
secret
cellular
immun
respons
cytolyt
lymphocyt
varieti
type
cell
produc
protein
henc
cell
type
transduc
plasmid
dna
mrna
relev
discuss
later
rel
less
interest
mrna
compar
plasmid
dna
platform
technolog
decad
led
recent
explos
interest
progress
mrna
transient
natur
messeng
rna
possibl
asset
process
wherebi
organ
control
product
desir
protein
due
rnase
wide
present
instabl
mrna
signific
reason
lack
interest
mrna
drug
addit
rna
long
known
immunolog
activ
molecul
exampl
poli
c
polyinosinepolycytidyl
acid
synthet
analog
dsrna
doublestrand
rna
agonist
long
use
immunostimulatori
mimic
viral
infect
test
adjuv
increas
immun
respons
experiment
vaccin
mrna
number
immunostimulatori
mechan
may
mrna
use
vaccin
cancer
immunotherapeut
discuss
howev
properti
contribut
lower
degre
interest
mrna
versu
plasmid
dna
gene
therapi
applic
provis
miss
defect
protein
immun
respons
either
protein
vector
deliveri
system
goal
two
develop
import
chang
percept
realiti
mrna
demonstr
weissman
kariko
use
modifi
nucleosid
made
vitrotranscrib
mrna
less
immunogen
followup
work
show
use
pseudouridin
instead
uridin
result
mrna
stabl
increas
translat
capac
use
modifi
nucleosid
thu
address
key
issu
mrna
increas
product
encod
protein
decreas
innat
immunogen
addit
work
explor
use
nucleosid
substitut
cytidin
improv
stage
perhap
use
review
structur
mrna
design
drug
vaccin
deliveri
incorpor
element
improv
stabil
protein
express
mrna
compris
cap
untransl
region
utr
also
call
leader
rna
code
sequenc
stop
signal
utr
poli
tail
molecul
provid
templat
cytoplasm
cell
translat
ribosom
trna
encod
protein
make
multipl
copi
protein
mrna
templat
amplif
provid
quantit
advantag
per
molecul
compar
provid
individu
protein
howev
offset
numer
advantag
addit
instabl
mrna
thought
one
molecul
mrna
escap
endosom
cytoplasm
amplif
translat
mrna
protein
overcom
loss
ineffici
degrad
transduct
process
anoth
obviou
implic
compar
plasmid
dna
must
enter
nucleu
cell
mrna
need
present
cytoplasm
elimin
addit
cellular
ie
nuclear
membran
plasmid
dna
need
cross
hand
plasmid
dna
stabl
mrna
dna
molecul
result
product
multipl
mrna
molecul
thu
theoret
advantag
one
boil
realiti
net
stabil
plasmid
dna
versu
mrna
final
formul
well
effici
target
desir
cell
transduct
cytoplasm
nucleu
follow
effici
transcript
plasmid
dna
result
amplif
dna
mrna
translat
mrna
whether
transcrib
dna
vitrotranscrib
mrna
protein
also
result
amplif
lower
quantiti
antigen
protein
presum
need
vaccin
due
amplif
immun
respons
antigen
compar
amount
protein
might
need
therapeut
diseas
target
addit
wherea
gene
therapi
longlast
even
perman
product
therapeut
protein
desir
vaccin
like
benefit
transient
natur
antigen
follow
boost
exampl
develop
high
affin
antibodi
occur
antigen
becom
scarcer
subsequ
boost
antigen
expand
product
high
affin
antibodi
rel
temporari
natur
presum
small
amount
protein
produc
mrna
would
fit
paradigm
mrna
present
great
enough
quantiti
persist
activ
long
enough
produc
suffici
amount
protein
antigen
stimul
desir
immun
respons
dna
vaccin
likewis
demonstr
produc
encod
protein
limit
period
time
although
like
longer
mrna
construct
given
greater
inher
stabil
plasmid
dna
compar
mrna
plasmid
dna
shown
persist
muscl
six
month
nonintegr
fashion
note
abil
make
either
plasmid
dna
mrna
construct
quickli
simpli
know
genet
sequenc
desir
antigen
make
plasmid
dna
mrna
much
faster
technolog
compar
current
approach
produc
vaccin
need
epidem
emerg
diseas
five
make
construct
rel
temporari
presenc
vivo
encod
protein
amplif
immun
system
respond
even
small
amount
express
protein
manufactur
advantag
gener
rapid
process
compar
drug
recombin
protein
intrins
immunostimulatori
properti
plasmid
dna
make
compel
rational
vaccin
view
best
initi
target
widespread
develop
effort
technolog
manufactur
plasmid
dna
consid
one
strength
make
platform
technolog
process
could
essenti
use
regardless
gene
encod
moreov
process
bacteri
ferment
fairli
simpl
sinc
product
plasmid
grown
bacteria
escherichia
coli
plasmid
dna
rel
stabl
make
purif
straightforward
contrast
timeconsum
process
earlier
gener
vaccin
requir
find
way
grow
pathogen
make
weaker
inactiv
histor
process
develop
vaccin
includ
manufactur
process
long
could
reach
decad
eg
chicken
pox
vaccin
advent
recombin
protein
provid
simpler
mean
make
vaccin
antigen
one
elimin
need
work
virul
pathogen
manufactur
howev
still
drawback
ensur
antigen
crucial
antigen
correct
posttransl
modif
glycosyl
differ
host
cell
yeast
baculoviru
compar
human
antigen
properli
fold
recombin
protein
gener
also
need
solubl
provid
challeng
protein
transmembran
domain
need
either
antigen
necessari
oligomer
eg
hiv
envelop
recombin
protein
administ
exogen
eg
given
immun
also
inher
limit
stimul
major
histocompat
complex
mhc
class
irestrict
cytolyt
lymphocyt
ctl
discuss
later
mrna
made
vitro
transcript
start
linear
dna
templat
perform
vitro
transcript
get
rid
templat
digest
dnase
point
mrna
purifi
manufactur
mrna
vitro
transcript
thu
even
appeal
manufactur
plasmid
dna
also
gener
process
ie
independ
gene
insert
essenti
chemic
process
anim
cellular
compon
although
cost
potenti
greater
graphic
detail
variou
step
suggest
possibl
improv
process
seen
refer
manufactur
process
might
guid
pharmaceut
product
good
manufactur
practic
gmp
guidelin
rather
biolog
like
advantag
cours
formul
addit
immunomodul
adjuv
deliveri
system
may
increas
complex
cost
manufactur
either
mrna
plasmid
dna
dna
vaccin
manufactur
entiti
note
stabil
particularli
supercoil
note
stabil
reflect
even
vivo
sinc
plasmid
detect
nonintegr
form
muscl
six
month
follow
inject
although
ubiqu
rnase
result
instabl
nativ
mrna
signific
reason
delay
develop
mrna
actual
manufactur
mrna
stabl
liquid
lyophil
form
report
stabl
two
year
room
temperatur
invers
relationship
stabil
temperatur
report
rabi
mrna
vaccin
still
effect
preclin
protect
sever
month
temperatur
rang
high
stabil
mrna
vial
product
ie
protect
rnase
separ
consider
stabil
vivo
formul
deliveri
devic
may
caus
shear
deliveri
key
factor
final
stabil
deliv
product
mani
vaccin
antibodi
play
key
role
protect
cell
transfect
plasmid
dna
mrna
vaccin
profession
antigen
present
cell
apc
order
produc
antigen
protein
stimul
b
cell
cellular
immun
respons
notabl
ctl
thought
import
tumor
immunotherapi
well
potenti
play
role
protect
certain
infecti
diseas
eg
tuberculosi
tb
hiv
malaria
vaccin
effect
multipl
strain
viru
influenza
even
though
ctl
alon
would
provid
steril
immun
order
vaccin
gener
mhc
class
irestrict
ctl
antigen
either
need
produc
insid
profession
apc
cell
antigen
crosspres
apc
stimul
ctl
direct
way
ensur
deliveri
gene
encod
antigen
profession
apc
transfect
cell
vitro
prior
administ
transfect
cell
back
patient
inde
largest
number
mrna
clinic
trial
current
underway
notabl
cancer
immunotherapi
involv
ex
vivo
transfect
cell
mrna
encod
tumor
antigen
follow
reinfus
transfect
cell
patient
cumbersom
process
make
product
nonperson
product
vial
direct
administr
plasmid
dna
mrna
patient
prefer
conveni
cost
time
plasmid
dna
shown
effect
stimul
ctl
capabl
protect
mice
influenza
caus
strain
differ
strain
encod
antigen
deriv
plasmid
dna
inject
intramuscularli
im
primarili
transduc
muscl
cell
rather
profession
antigen
present
cell
apc
mechan
wherebi
mhc
class
irestrict
ctl
gener
need
explain
found
crossprim
appear
key
mechan
gener
ctl
follow
dna
vaccin
immun
directli
demonstr
experi
chimer
mice
use
bonemarrow
deriv
dendrit
cell
muscl
cell
cell
observ
translat
protein
encod
directlyinject
plasmid
dna
efficaci
preclin
model
rais
hope
plasmid
dnabas
ctlinduc
vaccin
could
develop
would
protect
multipl
strain
hiv
influenza
produc
univers
flu
vaccin
current
exist
influenza
vaccin
depend
upon
strainspecif
antibodi
result
strainspecif
strainlimit
protect
similarli
mrna
deliv
liposom
shown
earli
capabl
induc
ctl
uptak
mrna
also
mainli
nonimmun
cell
includ
muscl
cell
plasmid
dna
mrna
also
develop
indic
vaccin
gene
therapi
deliveri
plasmid
dna
mrna
specif
tissu
cell
may
thu
intent
direct
part
mode
deliveri
inject
rout
formul
entiti
anion
due
neg
charg
phosphat
group
variou
formul
util
polyc
thu
biodistribut
molecul
depend
simpli
inher
charg
size
plasmid
mrna
net
charg
compon
formul
effect
lipid
signific
effort
expend
take
advantag
system
employ
certain
virus
notabl
alpha
virus
util
strategi
selfamplif
key
viral
protein
selfamplifi
replicon
system
develop
viral
vector
plasmid
dna
mrna
construct
encod
viral
protein
result
transduc
cell
produc
mani
copi
mrna
encod
protein
interest
ie
antigen
without
make
whole
viral
particl
thu
given
dna
mrna
vector
significantli
mrna
encod
antigen
henc
antigen
protein
made
preclin
model
result
increas
potenc
vector
per
molecul
vector
basi
reason
increas
efficaci
may
simpli
increas
amount
antigen
produc
dsrna
intermediari
result
increas
product
interferon
subsequ
immunolog
effect
although
dsrna
also
possibl
deleteri
effect
see
dna
mrna
vaccin
often
thought
simpli
express
system
desir
protein
neither
immunolog
inert
dna
vector
base
bacteri
plasmid
vitro
transcrib
mrna
activ
innat
immun
system
dna
plasmid
via
cpg
motif
stimul
cpg
success
use
adjuv
recombin
proteinbas
hepat
b
vaccin
licens
impact
immunogen
dna
vaccin
increas
number
cpg
motif
plasmid
less
clear
fact
certain
dna
vaccin
effort
notabl
steinman
group
therapi
autoimmun
diseas
specif
switch
cpg
motif
gpg
motif
guanin
connect
via
phosphodiest
bond
anoth
guanin
compet
cpg
motif
bind
receptor
effort
specif
decreas
help
human
clinic
studi
see
doublestrand
structur
dna
plasmid
also
thought
immun
stimul
nontlr
mechan
fact
plasmid
dna
also
act
pathway
cytosol
receptor
result
gener
type
interferon
act
adjuv
gener
immun
respons
antigen
encod
plasmid
dna
vaccin
note
use
modifi
nucleosid
construct
mrna
one
method
decreas
reactogen
vitro
transcrib
mrna
howev
mrna
act
via
multipl
pathway
includ
innat
system
via
tlr
via
cytoplasm
protein
pkr
oa
rigi
multipl
rout
activ
result
sever
effect
addit
inflamm
includ
inhibit
mrna
replic
via
pathway
affect
interferon
via
trif
stall
translat
rna
degrad
variou
activ
could
decreas
potenc
mrna
net
decreas
protein
product
seen
preclin
hiv
mrna
vaccin
complex
cation
lipid
also
rais
issu
effect
repeat
dose
mrna
previou
inject
result
environ
decreas
translat
increas
rna
degrad
although
simpli
chang
inject
site
may
potenti
circumv
particular
issu
molecular
entiti
introduc
gener
manufactur
vitrotranscrib
mrna
remain
leftov
contamin
nucleosid
triphosph
dna
templat
dsrna
also
quit
immunostimulatori
therefor
need
purifi
follow
product
mrna
potenti
issu
due
variou
inflammatori
effect
mrna
vaccin
upon
clinic
efficaci
safeti
summar
tabl
discuss
possibl
util
rnainduc
inflamm
vaccin
demonstr
fact
one
first
use
rna
vaccin
includ
noncod
rna
human
clinic
trial
adjuv
rabi
vaccin
compos
inactiv
viru
although
effort
replac
rabi
vaccin
util
mrna
encod
rabi
antigen
discuss
continu
evalu
noncod
rna
adjuv
ongo
clinic
test
variou
cancer
without
provis
antigen
see
flip
side
possibl
benefici
adjuv
inflamm
howev
potenti
toxic
mrna
vaccin
toxic
seen
antivir
anticanc
drug
contain
unnatur
nucleosid
analogu
toxic
predict
preclin
studi
due
speci
differ
human
anim
use
preclin
safeti
test
seen
drug
contain
unnatur
modifi
nucleosid
clinic
advers
effect
includ
myopathi
caus
mitochondri
toxic
lactic
acidosi
pancreat
lipodystrophi
liver
steatosi
nerv
damag
certain
one
fatal
inde
toxic
report
mrna
preclin
along
limit
human
advers
event
liver
toxic
observ
preclin
studi
one
potenti
mrna
therapeut
deliv
lipid
nanoparticl
criglernajjar
syndrom
select
lowesthang
fruit
target
low
dose
protein
need
seriou
enough
appar
halt
work
particular
entiti
least
formul
formul
mrna
thought
potenti
play
role
toxic
repeat
dose
use
nevertheless
observ
toxic
may
concern
vaccin
well
sinc
even
live
replic
virus
viral
vector
vaccin
gener
immunogen
subunit
vaccin
need
repeat
dose
addit
mrna
vaccin
clinic
trial
appear
need
formul
mrna
vaccin
clinic
trial
infecti
diseas
compani
describ
formul
lipid
nanoparticl
whether
formul
use
criglernajjar
studi
publicli
known
selflimit
local
system
advers
event
ae
seen
human
clinic
trial
mrna
rabi
vaccin
although
summar
still
indic
vaccin
gener
safe
describ
clinic
trial
section
may
also
reflect
inflammatori
natur
mrna
result
highlight
potenti
toxic
downsid
inflammatori
activ
mrna
vaccin
advers
effect
seen
extent
plasmid
dna
also
note
provid
monoclon
antibodi
whether
prevent
treat
infecti
diseas
therapeut
applic
would
like
requir
repeat
administr
mrna
might
increas
potenti
toxic
may
also
impact
upon
potenc
due
effect
mrna
upon
decreas
translat
etc
via
inflammatori
effect
thu
may
still
work
progress
find
best
balanc
inflamm
deleteri
toxic
via
har
adjuv
activ
mrna
limit
suppress
inher
toxic
vaccin
immunotherapeut
involv
optim
nucleosid
substitut
design
element
mrna
construct
includ
immunostimul
andor
specif
formul
deliveri
devic
rout
administr
mechan
mrna
inflamm
relev
potenti
efficaci
safeti
vaccin
also
review
elsewher
aptli
refer
yin
yang
innat
immun
dna
vaccin
initi
enter
human
clinic
trial
concern
rais
theoret
possibl
caus
autoimmun
dna
would
integr
genom
rational
concern
autoimmun
antidna
antibodi
hallmark
variou
autoimmun
diseas
date
preclin
test
care
clinic
monitor
shown
dna
vaccin
induc
worsen
autoimmun
fact
human
clinic
trial
employ
dna
vaccin
therapi
two
autoimmun
diseas
diabet
mellitu
multipl
sclerosi
gave
encourag
result
human
clinic
trial
therapeut
benefit
dna
vaccin
mrna
propos
mechan
possibl
autoimmun
respons
via
induct
type
interferon
may
result
inflamm
possibl
autoimmun
respons
includ
work
show
respons
seen
mice
similar
seen
human
influenza
mrna
vaccin
construct
via
human
via
cytoplasm
rna
sensor
mice
human
dna
vaccin
need
evalu
us
nation
institut
health
nih
recombin
advisori
committe
prior
human
clinic
trial
unlik
viral
vector
gene
therapi
nevertheless
signific
safeti
studi
initi
requir
evalu
possibl
integr
plasmid
dna
host
genom
result
studi
human
vaccin
licens
dna
vaccin
fish
well
mani
human
studi
dna
vaccin
demonstr
safeti
littl
concern
exist
regard
integr
comparison
state
mrna
offer
advantag
rna
integr
genom
dna
without
presenc
viral
element
retroviru
enabl
integr
revers
transcriptas
integras
howev
herv
human
endogen
retrovirus
whose
remnant
perman
part
human
genom
retroviruslik
sequenc
compris
human
genom
addit
recipi
mrna
drug
vaccin
may
alreadi
infect
retroviru
eg
hiv
thu
provid
theoret
mean
provis
protein
need
integr
nevertheless
risk
integr
remain
point
extrem
unlik
mrna
even
theoret
standpoint
longer
signific
concern
plasmid
dna
mean
mrna
offer
clear
advantag
compar
plasmid
dna
regard
regulatori
perspect
mrna
prophylact
vaccin
appear
consid
gene
therapi
product
similar
dna
vaccin
five
plasmid
dna
product
four
vaccin
receiv
licensur
veterinari
applic
includ
fish
vaccin
infecti
hematopoiet
necrosi
viru
licens
vaccin
salmon
pancrea
diseas
licens
dog
cancer
immunotherapeut
vaccin
melanoma
licens
origin
base
upon
comparison
histor
control
us
submiss
european
medicin
agenc
applic
withdrawn
compani
state
prioriti
chang
justifi
invest
research
develop
answer
remain
question
vaccin
west
nile
viru
wnv
prevent
hors
licens
although
longer
use
favor
previous
licens
kill
viru
vaccin
unpublish
reason
yet
promis
observ
equin
wnv
dna
vaccin
abl
protect
variou
speci
bird
wnv
includ
california
condor
credit
us
center
diseas
control
cdc
scientist
save
endang
speci
potenti
extinct
fifth
plasmid
dna
product
licens
veterinari
use
plasmid
encod
growth
hormon
releas
hormon
ghrh
given
via
electropor
pregnant
sow
result
litter
increas
number
surviv
piglet
higher
birthweight
licensur
immunogen
equin
wnv
vaccin
signific
human
dna
vaccin
effort
first
reason
scientist
often
state
dna
vaccin
good
induc
antibodi
yet
dna
vaccin
induc
neutral
antibodi
suffici
titer
protect
licensur
hors
also
signific
antibodi
made
hors
frequent
lack
potenc
dna
vaccin
human
trial
consid
reflect
size
human
compar
usual
small
preclin
anim
model
relat
observ
equin
wnv
dna
vaccin
human
clinic
trial
wnv
dna
vaccin
human
subject
gener
titer
antibodi
consid
protect
hors
subsequ
studi
use
construct
stronger
promot
older
adult
gener
consid
senesc
immun
system
respond
licens
vaccin
influenza
vaccin
poorli
younger
person
neutral
antibodi
respons
good
younger
adult
clinic
trial
dna
vaccin
ebola
marburg
virus
individu
likewis
gener
antibodi
boostabl
observ
demonstr
dna
vaccin
capabl
induc
antibodi
human
relev
titer
suggest
limit
technolog
per
se
gener
effect
antibodi
rather
target
optim
construct
key
element
much
find
right
target
monoclon
antibodi
mab
need
mab
becom
effect
anticanc
agent
also
note
first
two
zika
vaccin
brought
human
clinic
trial
dna
vaccin
underscor
point
made
earlier
eas
make
dna
mrna
vaccin
consid
tremend
advantag
rapid
respons
emerg
epidem
diseas
addit
variou
diseas
dna
vaccin
use
alon
result
promis
human
clinic
immun
respons
varieti
clinic
trial
sever
diseas
hiv
plasmid
dna
prime
follow
heterolog
boost
result
signific
potenc
gener
immun
respons
includ
ctl
addit
mention
phase
ii
studi
treatment
two
autoimmun
diseas
diabet
multipl
sclerosi
yield
encourag
clinic
respons
may
mechanist
due
part
design
vector
avoid
cell
respons
gener
seen
plasmid
util
diseas
moreov
clinic
trial
dna
vaccin
cancer
therapi
util
electropor
provid
encourag
result
includ
cervic
carcinoma
situ
well
head
neck
cancer
relat
human
papillomaviru
hpv
infect
clinic
trial
dna
vaccin
cancer
includ
use
dna
encod
fusion
protein
includ
tumor
ctl
epitop
helper
stimul
therefor
even
though
human
dna
vaccin
licens
exist
data
provid
evid
immunogen
earli
stage
evid
clinic
effect
human
certain
antigensdiseas
well
efficaci
anim
rang
fish
hors
remaind
special
issu
deal
effort
ongo
clinic
trial
thu
elabor
upon
prophylact
vaccin
human
trial
infecti
diseas
util
mrna
encod
antigen
shown
tabl
phase
trial
known
formul
list
describ
result
refer
along
clinic
trial
identifi
number
rabi
vaccin
effort
util
licens
vaccin
rna
adjuv
discuss
list
tabl
replac
vaccin
use
mrna
encod
rabi
viru
glycoprotein
follow
either
id
im
inject
rabi
mrna
vaccin
boostabl
antibodi
obtain
howev
group
solicit
system
advers
event
includ
ten
patient
inject
patient
grade
three
ie
seriou
lifethreaten
advers
event
although
conclus
vaccin
gener
safe
reason
toler
profil
second
construct
rabi
clinic
test
note
earlier
one
compani
initi
highlight
focu
therapeut
diseas
area
repriorit
vaccin
possibl
due
recognit
low
amount
antigen
actual
produc
mrna
coupl
low
amount
protein
need
vaccin
amplif
immun
system
possibl
respons
emerg
diseas
zika
epidem
possibl
influenc
liver
toxic
seen
preclin
studi
deliv
even
low
amount
mrna
need
diseas
criglernajjar
see
lipid
nanoparticl
also
use
compani
vaccin
formul
although
known
relat
formul
use
criglernajjar
compani
publish
rel
littl
peerreview
scientif
literatur
relat
clinic
trial
refer
avail
provid
within
tabl
although
case
assumpt
made
preclin
construct
refer
construct
antigen
one
clinic
trial
trial
util
noncod
rna
adjuv
list
studi
includ
use
noncod
rna
adjuv
licens
rabi
vaccin
result
improv
immunogen
mainli
mild
ae
two
patient
sever
limit
influenzalik
symptom
studi
ongo
use
noncod
rna
adjuv
cancer
applic
use
coadminist
mrnaencod
antigen
mrna
therapi
hiv
infect
test
two
clinic
trial
administ
intranod
although
immunogen
phase
trial
appear
promis
second
phase
trial
termin
interim
analysi
due
lack
immunogen
seen
placebo
one
compani
recent
announc
press
releas
citat
found
pubm
entiti
clinic
trial
initi
mrna
encod
monoclon
antibodi
use
prevent
chikungunya
viru
infect
cancer
therapi
four
complet
studi
two
per
differ
mrna
construct
termin
complet
prostat
cancer
fail
demonstr
efficaci
new
trial
includ
cancer
initi
varieti
group
variou
mrna
construct
anoth
approach
develop
steer
toward
person
cancer
immunotherapeut
vaccin
product
via
librari
mrna
code
differ
antigen
combin
person
individu
mention
earlier
much
larger
number
trial
cancer
util
mrna
ex
vivo
transfect
dendrit
cell
reinfus
patient
review
elsewher
summari
despit
excit
preclin
efficaci
mrna
rememb
mani
way
mrna
field
recapitul
occur
plasmid
dna
year
ago
seemingli
almost
diseas
could
prevent
treat
preclin
anim
diseas
model
administr
unformul
plasmid
encod
key
antigen
therefor
one
must
keep
mind
preclin
immunogen
even
protectiontherapi
human
immunogen
low
hurdl
predict
human
efficaci
one
reason
challeng
mani
diseas
evalu
scientist
know
immun
respons
combin
immun
respons
antigen
target
crucial
element
efficaci
vaccin
technolog
alon
piec
puzzl
tabl
summar
main
advantag
disadvantag
mrna
vaccin
comparison
dna
vaccin
report
phase
clinic
trial
result
mrna
vaccin
encourag
although
result
first
rabi
mrna
vaccin
publish
peer
review
literatur
result
human
metapneumoviru
parainfluenza
viru
respiratori
syncyti
viru
rsv
phase
studi
announc
via
press
releas
thu
detail
avail
target
rsv
vaccin
mrna
publicli
disclos
time
phase
studi
initi
date
studi
appear
list
clinicaltrialsgov
whether
immun
respons
suffici
level
type
need
immun
respons
necessari
durat
result
protect
efficaci
unknown
necessarili
predict
phase
studi
one
also
ignor
report
toxic
seen
rabi
mrna
vaccin
includ
limit
system
ae
major
patient
even
grade
three
ae
patient
follow
dose
mrna
via
differ
rout
although
conclus
vaccin
gener
safe
known
whether
preclin
hepat
toxic
prove
go
result
particular
criglernajjar
mrna
candid
relev
mrna
vaccin
studi
compani
despit
low
dose
use
dose
mrna
formul
vaccin
studi
may
differ
comparison
dna
vaccin
clinic
trial
mg
dose
dna
im
boost
use
varieti
clinic
trial
limit
system
symptom
gener
good
immun
respons
dna
vaccin
year
sinc
first
public
preclin
protect
efficaci
still
work
progress
improv
potenc
find
right
antigen
target
remain
challeng
mrna
becom
clinic
product
dna
mrna
vaccin
monoclon
antibodi
bispecif
antibodi
simpl
concept
may
challeng
path
realiti
technolog
may
total
gener
mrna
may
even
complex
plasmid
dna
modif
modifi
nucleosid
plu
formul
need
stabil
deliveri
need
control
innat
immunostimulatori
activ
mrna
howev
also
offer
advantag
term
manufactur
avoid
need
anim
cellular
product
hope
fundament
key
challeng
solv
plasmid
dna
mrna
clinic
success
come
rapidli
although
occur
move
veterinari
licens
product
dna
vaccin
human
demonstr
much
still
need
understood
technolog
diseas
treat
prevent
